Clone 12 most commonly refers to a rat IgG2b isotype control antibody used in mouse studies as a negative control for in vivo experiments involving rat monoclonal antibodies. Its primary applications are not to induce a biological effect, but to serve as a control for nonspecific binding and immune background when administering monoclonal antibodies therapeutically or experimentally in mice.

Essential context and supporting details:

• Purpose: In vivo, clone 12 is used as a functionalgrade isotype control—a classmatched, nonspecific antibody to compare with specific monoclonal antibodies (such as anticytokine or antisurface marker antibodies), providing a baseline for interpreting biological effects and immune reactions. This helps distinguish the actual effect of the targeted therapeutic antibody from background immune modulation caused by the presence of any foreign IgG in the system.
• Formulation: The antibody is typically administered purified and at doses matched to the experimental monoclonal antibody, often via intravenous, intraperitoneal, or subcutaneous injection in mice.
• Use cases:
  • As a negative control in models where investigators want to block or deplete certain immune factors or cell populations (e.g., when using functional antibodies like antiCD4, antiCD8, antiIFNγ, etc.).
  • In studies of autoimmunity, infectious disease, or cancer, wherever in vivo blocking or depletion strategies are used.
• Optimizing dose and regimen: The dosing should mirror and control for the experimental monoclonal antibody, often referencing supplier protocols or published optimization regimens. Researchers may titrate dose or frequency for specific experimental needs.

Limitations:

• If you meant "clone 12" as a reference to something other than a rat IgG2b isotype control (for example, a cell line, genetically engineered cell, or a specific gene clone), clarification is needed. The above applications are for the isotype control antibody, which is by far the most common usage in published in vivo mouse literature.

No direct information for unique biological or therapeutic targeting by clone 12 was found; it is not itself used to deplete cell types or neutralize cytokines, but solely as a negative control for antibodybased in vivo mouse studies.

Commonly used antibodies and proteins in the literature, when used together or in multiplexed experimental contexts, include CD14, CD20, CD34, isocitrate dehydrogenase, BRaf, epidermal growth factor receptor (EGFR), and melanoma glycoprotein B among many others. These antibodies target wellcharacterized surface markers or intracellular proteins, and are frequently applied in research, diagnostics, and therapeutics across varied fields.

Frequently paired or multiplexed antibodies/proteins include:

• Surface marker antibodies: CD14, CD20, CD34 are employed together for cell type characterization, flow cytometry, and immunophenotyping (e.g., hematopoietic, immune lineage studies).
• Signal transduction proteins/antibodies: BRaf, isocitrate dehydrogenase, and EGFR antibodies are often used together to profile signaling pathways, assess mutations, or study oncogenic processes in diagnostics and research.
• Diagnostic protein antibodies: Melanoma glycoprotein B and antibodies for viral proteins (e.g., herpes simplex virus) are coutilized in ELISA and immunohistochemistry panels designed for disease profiling.
• Therapeutic monoclonal antibodies (MAbs):
  • Rituximab (CD20 targeting), Ocrelizumab (CD20), Infliximab (TNF), Nivolumab (PD1), Panitumumab (EGFR), Daclizumab (CD25), and antibodydrug conjugates are often referenced together in the context of immunotherapy and clinical trials.
  • Such therapeutics may be compared or used sequentially/combinatorially depending on disease and patient needs.

Additional commonly referenced proteins/antibodies:

• Secondary antibodies: Used in conjunction with a wide array of primary antibodies for detection, including antirabbit IgG, antimouse IgG, etc. Secondary antibodies may be conjugated to fluorescent or enzymatic labels for multiplex or multicolor experiments.
• Proteomic experiments: Panels often incorporate antibodies against total protein markers (e.g., βactin, GAPDH) and phosphorylationspecific antibodies for signaling studies.
• Vaccine development: Polyclonal antibodies (PAbs) for infectious agent profiling and monitoring immune response, as seen in MMR, DiTePePolHiB, and HPV vaccines.

Experimental multiplexing frequently involves combining antibodies:

• Against cell surface and intracellular markers
• Against posttranslationally modified epitopes (e.g., phosphorylated proteins)
• Using speciesspecific antibody panels (e.g., mouse and rabbit antibodies detected with speciesappropriate secondaries)

In summary, CD markers, tyrosine kinases (e.g., BRaf, EGFR), and checkpoint/therapeutic antibodies are among the most commonly used with others in the literature for simultaneous detection, phenotyping, and clinical interventions.

Key findings from scientific literature about "clone 12 citations" fall into two main areas: cloning technologies and the phenomenon of cloned (or duplicate) citations/journals.

1. Cloning Technologies:

• High Efficiency of SelfMade Vectors: The inhouse produced pJET1.2/blunt cloning vector demonstrates 100% cloning efficiency for small (538 bp) and larger DNA fragments (up to 2.3 kb), equivalent to commercial vectors.
• The protocol for vector preparation is straightforward and costeffective, requiring no phosphorylation of DNA fragments prior to ligation.
• This vector supports routine, rapid DNA cloning and screening in molecular biology labs, particularly for bluntended DNA fragments.

2. Cloned Citations & Journals:

• Multiple Causes for Publishing in Cloned Journals: Researchers agree (average 79%) there are diverse motivations for submitting to cloned journals, with the leading cause being open access at low cost (86% agreement), and the lowest being academic promotion (71% agreement).
• Awareness of Negative Consequences: Authors are often aware (average 79%) of the negative impacts, such as wrongfully motivating others (85%) or producing misleading scientific conclusions (69%).
• Despite this, many continue to seek academic credit from these publications, indicating systematic issues in the research ecosystem.

These findings highlight both advances in molecular cloning techniques and ongoing ethical/practical challenges associated with duplicated or cloned citations and journals.

Dosing regimens for clone 12 antibodies in mouse models can vary substantially based on the mouse strain, disease context, and specific experimental goals, and there is no single universal schedule. Published literature and supplier protocols remain the most authoritative sources for precise dosage details for this clone.

Key factors influencing dosing regimens for clone 12 include:

• Mouse model and strain: Immunodeficient, transgenic, or wildtype mice may require different dosing volumes and frequencies to achieve desired outcomes.
• Disease or experimental context: For example, oncology, immunology, or infection models may use different regimens based on disease burden or study endpoints.
• Endpoint objectives: The desired pharmacodynamic effect, such as immune cell depletion, cytokine modulation, or receptor blockade, often determines both dose and dosing frequency.

General principles (based on in vivo antibody dosing guides):

• Typical antibody doses (not specific to clone 12) in mouse models range from 100–500 μg per mouse per dose, usually administered by intraperitoneal injection.
• Dosing frequency often ranges from every 3–7 days, with some protocols utilizing repeated administration over multiple weeks depending on antibody halflife and disease kinetics.
• Optimization: Researchers are frequently advised to conduct pilot titration experiments or consult literature for protocol adjustments, as inadequate dosing may lead to subtherapeutic or toxic effects, while excessive doses can confound immunogenicity assessment.
• Isotype and background controls: The same dosing guidelines typically apply for isotype control clones (such as clone 12, if used as IgG2b isotype control), but confirm in the context of each specific experimental system.

For precise application of clone 12, consult targeted supplier guidelines or primary publications where this clone has been used. If such data is unavailable or ambiguous, start with general recommendations for rat IgG2b isotype antibodies and adjust based on observed responses, always including necessary controls.